Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.
about
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitroPathogenesis of human immunodeficiency virus infectionSurvivors Remorse: antibody-mediated protection against HIV-1.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism.Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoproteinBroad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical TriaInduction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodiesPrincipal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.Virus receptors: implications for pathogenesis and the design of antiviral agents.Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1.Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.Characterization of cell-binding properties of bovine herpesvirus 1 glycoproteins B, C, and D: identification of a dual cell-binding function of gB.A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibodyN-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entryPolyclonal bovine sera but not virus-neutralizing monoclonal antibodies block bovine leukemia virus (BLV) gp51 binding to recombinant BLV receptor BLVRcp1.Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 bindingAntibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding.Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralizationAmino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope proteinNative oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humansAutologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humansEffect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.
P2860
Q24563642-E012100D-F208-4772-B8AF-8E2BF9C22C80Q24634681-565D03D1-47DE-4279-B31D-31F76CC40B8BQ30238730-A100CA3E-7839-4634-B99E-E5D9EF3ADB3CQ31143293-E6A8A249-6997-4C96-8B12-0B46E8FF2AF7Q33564746-14A42BAC-8A52-4B86-9E09-5592796E14ABQ33933098-5D3AF3EE-446E-4A4D-A57F-4D3F80AB15AFQ33933980-3AB2BBE6-B9EB-46E3-997D-858C8757F4CEQ33936268-E767FB39-46CE-4218-A5B0-9A1D324418FBQ33937274-4E97C095-9BB5-4170-AFB8-A160D05DDC6CQ33983104-A4DE8073-03D3-459A-985A-0618F276F22BQ34171212-F1588383-895C-49AF-BAD7-F452045E0D95Q34171623-01E9553B-C54F-4232-A270-23ED0C43F448Q34201595-A68B6C03-85AB-4321-8C69-A9A4CF2C2FEAQ34301897-C1ECA821-D6C3-4C3C-BB07-54C6AC5A102CQ34332284-C8A2A7B8-A134-4332-9B93-9F099F037888Q35227014-3F0AB686-C991-4FBB-B9E7-8088D7329DE6Q35366667-94A3D8A1-5F0D-47F1-B19E-70191AAE350CQ35828735-547414FE-ADF6-42A3-9F20-3922D0E86BC9Q35837553-E5DBB820-971A-4356-BF90-9DCC5ABC59CDQ35844270-FC408AE2-E8D6-4FC2-B7D2-EB4960BEFD03Q35864006-AB84BC02-279C-4C53-B5DE-188441E72B3AQ35866030-6FB1AF7B-89FA-451E-A394-B8329A8B56A6Q35870879-C44CBEDD-F379-4322-88A4-98BE9F1B8FF2Q35873035-52F7C636-0E79-4A16-B684-CC8435B04007Q35881609-A365B1E3-080F-4914-9351-B0D3C9C8AB01Q35930918-39CA0651-1DAC-42EE-9712-5FF9ADAB396EQ36230268-38A4BA9E-1014-4EA9-9118-91C3C4D1BDCDQ36353645-D3FFDA55-9FD9-48BE-960D-791BD1382F55Q36380741-0191136B-F6ED-4145-9048-AE4FD1675118Q36622298-7B18EE10-10CE-42A3-A2E3-1ADCB6D898DFQ36626451-BED3BB85-BA25-4589-AAA3-3D65406222A6Q36632605-0EF4061E-F050-4A54-B3CE-A4CBE5EC19A1Q36633402-AB2D6678-3934-4BF5-82F4-2446C3D3D7D1Q36634149-4ACB8EDB-B73F-47E2-8623-D411D2B94F2BQ36634341-77A450D6-4E0D-47C9-A3D6-4F8A957D9B31Q36641374-56A714E8-7781-4BE9-8F98-4D4853BBBD3FQ36644253-AF0FB74E-2240-4CB0-B2BD-E4D768939D38Q36649240-932AE097-100C-413E-B689-D22CF539FC61Q36649958-D6BB4F29-B1FE-4DA2-88C0-E7238558AE9EQ36652422-9FB64416-D657-448C-BAD0-027C6A756A52
P2860
Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Neutralizing antibodies to an ...... prevent gp120 binding to CD4.
@en
type
label
Neutralizing antibodies to an ...... prevent gp120 binding to CD4.
@en
prefLabel
Neutralizing antibodies to an ...... prevent gp120 binding to CD4.
@en
P2093
P2860
P1433
P1476
Neutralizing antibodies to an ...... prevent gp120 binding to CD4.
@en
P2093
A J Langlois
C B McDanal
D P Bolognesi
J S McDougal
M A Skinner
T J Matthews
P2860
P304
P407
P577
1988-11-01T00:00:00Z